bioRASI

37 articles about bioRASI

• Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial

  1/4/2023

  Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects With Mild-to-Moderate Dementia of the Alzheimer's Type.

• 

  Stem Cell Therapy: The Latest Contender in Pharma's Fight Against Long COVID

  5/2/2022

  Therapeutic Solutions International is targeting long COVID with a new stem cell therapy, as Tonix and Pfizer explore their own treatment options.
• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• Biorasi Welcomes Nephrologist Dr. Jamie Dwyer to Scientific Advisory Board

  7/1/2021

  Biorasi , a leading global, full-service contract research organization (CRO), is proud to announce the appointment of Jamie P. Dwyer, MD to the position of Scientific Advisory Board (SAB) member.

• Biorasi Welcomes Oncologist Dr. Alex Adjei to Scientific Advisory Board

  5/27/2021

  Biorasi, a leading global full-service contract research organization, is proud to announce the appointment of Alex A. Adjei, MD, PhD, FACP to the position of Scientific Advisory Board member.

• Biorasi Receives ISO 9001:2015 Certification for Quality Management

  5/11/2021

  Biorasi, a leading global full-service contract research organization, is proud to announce the achievement of ISO 9001:2015 certification.

• Biorasi Welcomes Hematologist Dr. Robert S. Negrin to Scientific Advisory Board

  5/4/2021

  Biorasi , a leading global full-service contract research organization (CRO), is proud to announce the appointment of Robert S. Negrin, MD to the position of Scientific Advisory Board (SAB) member.

• Biorasi’s Jimmy El Hokayem Appointed to Scientific Advisory Board for the Foundation for Angelman Syndrome Therapeutics

  3/2/2021

  Biorasi, a leading global full-service contract research organization, has announced the appointment of Jimmy El Hokayem, Ph.D., head of the company’s Neurology and Regenerative Medicine Center of Excellence to the Scientific Advisory Board for the Foundation for Angelman Syndrome Therapeutics.

• Biorasi Selects IBM Watson Health as Preferred Vendor

  9/2/2020

  Biorasi , a leading global full-service contract research organization (CRO), announced today that they have selected IBM Watson Health (IBM) as a preferred vendor. This relationship with IBM Watson Health expands Biorasi’s capabilities in clinical trial execution and management through IBM’s Clinical Development (ICD) platform – a clinical data management system (CDMS) designed to help bring efficiency and speed to the clinica

• Biorasi Recognized on Inc. 5000 List of Fastest-Growing Private Companies

  8/26/2020

  Biorasi , a leading global full-service contract research organization (CRO), has been named on the Inc. 5000 list of the fastest-growing private companies for 2020. This prestigious ranking from Inc. magazine distinguishes Biorasi as an industry leader in the health services and clinical trial management industries. “Biorasi is honored to be included in the Inc. 5000 again this year,” said Scott Nenninger, CFO at Biorasi.

• Biorasi Kicks-Off Third COVID-19 Clinical Trial for 2020

  7/9/2020

  Biorasi , a leading global full-service contract research organization (CRO), has announced the start of the company’s third COVID-19 clinical trial for 2020. Taking place across the United States and Europe, the goal of the study is to evaluate the efficacy and safety of the candidate drug as an antiviral agent in hospitalized patients diagnosed with COVID-19 infections. “We are proud to have been selected as the CRO partner

• bioRASI Joins GPhA Biosimilar Council

  9/1/2016

• bioRASI Enhances Safety And Pharmacovigilance Capabilities, Promotes Mark Vieder To Vice President

  6/15/2016

• bioRASI Sponsors American Kidney Fund Event

  10/23/2015

• bioRASI Is On The 2015 Inc. 500 List

  8/13/2015

• bioRASI's Dermatology Trial Recruits Over 1,000 Rosacea Patients In 3.5 Months

  8/11/2015

• bioRASI Selects Medidata Solutions, Inc.'s Cloud-Based Platform For Optimal Trial Operations

  3/31/2015

• CRO bioRASI Will Hire Up to 30 Employees

  2/11/2015

• bioRASI Names David Judson Vice President, Chief Compliance Officer

  6/15/2012

• bioRASI to Exhibit at the 2012 GPhA Annual Meeting in Orlando, FL

  2/22/2012